infoedu.milaulas.com

Ace Therapeutics, a premier provider of preclinical contract research services focused on obesity and metabolic disorders, today reinforces its position as a trusted partner for biotech and pharmaceutical innovators with its comprehensive obesity CRO services. Leveraging a decade of translational pharmacology experience, Ace Therapeutics combines advanced in vivo pharmacology, real-time behavioral monitoring, and multi-dimensional biomarker analysis to transform obesity research into actionable insights for next-generation metabolic therapies.

Obesity, a chronic metabolic disorder defined by a BMI ≥30 kg/m² (per WHO criteria), is linked to increased risks of type 2 diabetes, cardiovascular diseases, and neurodegenerative disorders. With breakthroughs in therapies such as GLP-1 receptor agonists (e.g., Semaglutide) and dual GLP-1/GIP agonists driving demand for rigorous preclinical validation, Ace Therapeutics' obesity CRO services are tailored to address the unique challenges of evaluating anti-obesity drug candidates—including those targeting GLP-1 pathways.

A cornerstone of Ace Therapeutics' offerings is its portfolio of validated, disease-relevant preclinical models, which include the Humanized GLP-1R Mouse Model—a CRISPR-Cas9-engineered model that replaces murine GLP-1R with the human receptor. This model reduces cross-species reactivity discrepancies, enabling precise species-specific pharmacodynamic profiling and target engagement studies for GLP-1-focused therapeutics. Validated using clinically relevant reference compounds (e.g., 15% body weight reduction at clinical equivalent doses), it is a centerpiece of Ace Therapeutics' GLP-1 preclinical CRO capabilities. Additional models include Diet-Induced Obesity (DIO) mice and rats (optimized for testing GLP-1 agonists and dual receptor agonists), ob/ob mice (for leptin-independent pathway research), and Zucker Fatty Rats (for comorbidity-focused studies), all designed to replicate human pathophysiology and meet global regulatory standards.

Beyond model access, Ace Therapeutics' obesity CRO services encompass end-to-end solutions for drug development: from phenotypic profiling and lead optimization to safety pharmacology and mechanism of action (MoA) studies. The company's multi-dimensional MoA research dissects both central (CNS) and peripheral pathways, utilizing technologies such as automated metabolic cage systems for real-time feeding behavior analysis, indirect calorimetry for energy expenditure profiling, and fiber photometry for neurocircuitry mapping. Its biomarker analysis platform—spanning ELISA, LC-MS/MS, RNA sequencing, and 16S rRNA sequencing—quantifies key metabolic, inflammatory, and neuroendocrine markers critical to evaluating GLP-1 and other anti-obesity therapies.

Ace Therapeutics also offers tailored support for diverse therapeutic modalities, including peptide/protein therapeutics (e.g., GLP-1 analogs), small molecules, cell and gene therapies, and multi-target agents. Its flexible, client-centric approach allows for customized study designs—from specialized diets to comorbidity induction (e.g., NAFLD, hypertension)—and mid-study adjustments to address emerging hypotheses, without compromising timelines or data integrity. All studies are conducted in-house under BSL-2 protocols, ensuring compliance with strict regulatory and ethical standards.

For biotech and pharmaceutical companies seeking to advance anti-obesity candidates—whether targeting GLP-1 pathways, novel receptors, or combination therapies—Ace Therapeutics' obesity CRO services provide a trusted, comprehensive solution to streamline preclinical research and drive therapeutic innovation.